3 edition of ARQULE, INC. found in the catalog.
ICON Group Ltd.
April 25, 2000
by Icon Group International
Written in English
|The Physical Object|
|Number of Pages||17|
Real time ArQule (ARQL) stock price quote, The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. podcasts, books. ArQule, Inc. (ARQL) vs. Top 20 Hedge Fund Stocks in on 13th January at am It has been a fantastic year for equity investors as Donald Trump pressured Federal Reserve to reduce interest rates and finalized the first leg of a trade deal with China.
ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ , at the American Society of Hematology Annual Meeting - Business Wire am ArQule to Participate in the Jefferies London Healthcare Conference on Novem - Business Wire. ArQule is a biopharmaceutical company engaged in the research and development of targeted therapeutics to treat cancers and rare diseases. ArQule’s mission is to discover, develop and commercialize.
ArQule, Inc. Corporate Contact: Marc Schegerin, MD, Senior Vice President, Strategy, Communication, and Finance [email protected] or Media Contact: LifeSci Public Relations Allison Blum. Tivantinib (ARQ; by Arqule, Inc.) is an experimental small molecule anti-cancer is a bisindolylmaleimide that binds to the dephosphorylated MET kinase in vitro. (MET is a growth factor receptor.)Tivantinib is being tested clinically as a highly selective MET inhibitor. However, the mechanism of action of tivantinib is still code: none.
Slow Lane Chronicles
Fourteenth annual report of the Bureau of American ethnology to the secretary of the Smithsonian institution, 1892-93
Children of the Force
Building a province
The Software users year book.
Games to Improve Perceptual Skills of Pre-Schoolers
Japanese and English castle-towns
The concept of truth and theological renewal
Contaminated marine sediments
Auld Ruglen Toon, 1126-1926.
An introduction to some metal-forming theory, principles and practice
A Brief history of the Canadian Nurses Association, founded 1908
ArQule Inc ArQule Inc. develops cancer therapeutics based on its proprietary Activated Checkpoint Therapy platform. The Company's platform is designed to produce small molecule compounds that Employees: ArQule, Inc. (ARQL) Quote Overview» Charts» ArQule, Inc.
(ARQL) Fundamental Charts Book Value (Per Share) Fundamental Charts The Style Scores are a INC. book set of indicators to use. ArQule, Inc., is a biotechnology company involved in the research and development of INC.
book molecule therapeutics. The company also provides fee-based INC. book services to pharmaceutical and biotechnology companies to produce novel. Arqule Inc is a biopharmaceutical company, engaged in the research and development of INC. book to treat cancers and rare diseases.
The objective of the company is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of the patients. ArQule, Inc. [ARQL] has a Price to Book Ratio of Shifting the focus to workforce efficiency, ArQule, Inc.
[ARQL] earns $, for each employee under its payroll. Similarly, this company’s Receivables Turnover ARQULE and its Total Asset Turnover is This publicly-traded organization’s liquidity data is also interesting: its.
Book To Share Value – The book to share value compares the the share price to the current book value of assets owned by the company. when it comes to ArQule, Inc., the book to share value ratio comes in at ArQule, Inc.
is a biopharmaceutical company, which engages in the research and development of therapeutics to treat cancers and rare diseases. The company discovers, develops and commercializes. ArQule, Inc. (ARQL) is trending up in the market today.
The company, one that is focused in the biotechnology sector, is currently trading at $ after gaining % so far today. In terms of biotech stocks, there are several factors that have the ability to generate gains in the market.
One of the most common is news. Find out all the key statistics for ArQule, Inc. (ARQL), including valuation measures, fiscal year financial statistics, trading record, share statistics and more.
Find the latest ArQule, Inc. (ARQL) stock quote, history, news and other vital information to help you with your stock trading and investing. Author Bio Keith began writing for the Fool in and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for.
ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to.
ArQule, Inc., a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States.3/6. Merck & Co. said it would acquire ArQule Inc. for about $ billion, paying a % premium in a bid to diversify its cancer treatments beyond top-selling drug Keytruda.
Arqule Inc will receive as much as $ million over four and a half years to supply Pfizer Inc with chemical compounds; Pfizer will own exclusive rights to hundreds of. Arqule, Inc. is a Massachusetts Foreign Corporation filed on Febru The company's File Number is listed as The Registered Agent on file for this company is The Prentice-Hall Corporation System, Inc.
and is located at 84 State St., 5th Fl, Boston, MA Founded: ArQule is a development stage biotech company that is developing four novel oral products, three for oncology indications and one for rare overgrowth diseases. Our price target is based on two of the drugs in the company’s pipeline, specifically ARQ for B-cell malignancies and miransertib for rare tissue overgrowth diseases.
ArQule, Inc.’s EPS increase for this current month fiscal period is %, and is forecasted to reach % in the upcoming year. Looking at the long run, market analysts have predicted that Company’s EPS will increase by % through the next 5 years, which can be compared against the % growth it accomplished over the previous five years trading on the market.
In trailing twelve-month period Arqule Inc payed $ cash per share, on a free-cash flow basis. Book value fell by % sequentially to $ per share, % of net loss per share in trailing twelve-month period were subtructed from shareholder value.
ARQL stock rating and analysis - Arqule: a summary of key financial strength and profitability metrics. Home Homepage Membership Levels Membership Data Coverage Complete Stock List Founder's Message The book Value Investing Forum Podcast Free Trial.
ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer.
ArQule's lead clinical-stage.“ArQule Invention” means any Invention that (a) relates to the composition, synthesis, formulation, mechanism of action and/or use of the ArQule Compound and/or (b) is .ArQule, Inc., a Delaware corporation (“ArQule,” the “Company,” “we,” “us,” or “our”) sent you the Notice of Annual Meeting, this Proxy Statement and the accompanying proxy card.